Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Integrated BiopharmaINBP 36 5-Year ROIIC % is -269.07 as of Jun. 2025. GuruFocus rates INBP with a GF Score™ of 36/100 and a GF Value™ of $0.26 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,708 Consumer Packaged Goods companies, Integrated Biopharma ranks worse than 98.19% on this metric.
5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year.
Integrated Biopharma's 5-Year ROIIC % for the quarter that ended in Jun. 2025 was -269.07%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Integrated Biopharma's 5-Year ROIIC % or its related term are showing as below:
INBP's 5-Year ROIIC % is ranked worse than 98.19% of 1708
companies
in the Consumer Packaged Goods industry
Industry Median: 3.565
vs INBP: -269.07
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Integrated Biopharma 5-Year ROIIC % Related Terms
Integrated Biopharma 5-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Integrated Biopharma's 5-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
INBP vs HCWC, PAVS, BABB: 5-Year ROIIC % Comparison
For the Packaged Foods subindustry, Integrated Biopharma's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integrated Biopharma 5-Year ROIIC % vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Integrated Biopharma's 5-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Integrated Biopharma's 5-Year ROIIC % falls into.
Integrated Biopharma's 5-Year ROIIC % for the quarter that ended in Jun. 2025 is calculated as:
5-Year ROIIC %
=
5-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
5-Year Incremental Invested Capital**
=
( 0.791638 (Jun. 2025) - 3.259 (Jun. 2020) )
/
( 17.717 (Jun. 2025) - 16.8 (Jun. 2020) )
=
-2.467362
/
0.917
=
-269.07%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Integrated Biopharma (INBP) has a 5-Year ROIIC % of -269.07 as of Jun. 2025. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on Integrated Biopharma and its competitors. According to the industry distribution chart, Integrated Biopharma ranks #1677 out of 1708 companies in the Consumer Packaged Goods industry, placing it in the top 98.2%.
Is Integrated Biopharma's 5-Year ROIIC % too high?
Integrated Biopharma's current 5-Year ROIIC % is -269.07. Based on the distribution chart, Integrated Biopharma ranks #1677 out of 1708 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, Integrated Biopharma has a GF Score™ of 36/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Integrated Biopharma's 5-Year ROIIC % compare to HCWC and PAVS?
According to the Consumer Packaged Goods industry distribution chart, Integrated Biopharma ranks #1677 out of 1708 companies for 5-Year ROIIC %. This places Integrated Biopharma in the lower half of its industry. The industry median 5-Year ROIIC % is 3.57. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year ROIIC % for a Consumer Packaged Goods company?
The median 5-Year ROIIC % among Consumer Packaged Goods companies is 3.57, based on 1,708 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year ROIIC % mean?
A high 5-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on Integrated Biopharma and its competitors. For the Consumer Packaged Goods industry, the median 5-Year ROIIC % is 3.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Integrated Biopharma's current 5-Year ROIIC % is -269.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integrated Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Integrated Biopharma (INBP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.26, compared to a current price of $0.16 — trading 38.5% below its estimated fair value. The current 5-Year ROIIC % is -269.07. Integrated Biopharma's overall GF Score™ is 36/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year ROIIC % calculated?
5-Year ROIIC % is calculated from a company's financial statements. For Integrated Biopharma (INBP), the current 5-Year ROIIC % is -269.07 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integrated Biopharma (INBP) Overvalued in 2026?
Based on GuruFocus' analysis, Integrated Biopharma stock appears to be undervalued.
The current stock price of $0.16 is trading 38.5% below its estimated GF Value™ of $0.26.
GuruFocus considers Integrated Biopharma to be Possible Value Trap.
Key valuation signals for INBP:
5-Year ROIIC %: -269.07
GF Value™: $0.26 vs. price of $0.16 (38.5% below fair value)
No single metric tells the full story. See the INBP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integrated Biopharma Inc is a pharmaceutical company engaged in manufacturing, distributing, marketing, and selling vitamins, nutritional supplements, and herbal products. It operates in two segments: Contract Manufacturing and Other Nutraceutical Businesses. Key revenue is generated from the Contract Manufacturing segment, which manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers.
36GF Score
Get the complete analysis for INBP
5-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INBP has been successfully added to your 
